LCN2 and type 2 diabetes mellitus: This study reveals a significant impact of empagliflozin, an SGLT2 inhibitor, in reducing the markers of tubular damage, KIM-1 and NGAL, in early-stage type 2 diabetes patients (Fig. 10).